MedPath

Study of Enterra Programming with Nocturnal Cycling in Gastroparetics

Not Applicable
Recruiting
Conditions
Gastroparesis Nondiabetic
Gastroparesis
Gastroparesis Due to Diabetes Mellitus
Registration Number
NCT05980455
Lead Sponsor
Enterra Medical, Inc.
Brief Summary

The purpose of this research study is to evaluate if different Enterra® device programming methods active during sleeping hours can maintain gastroparesis-related symptom relief and quality of life measures.

Participants in this study with existing Enterra® devices will be randomly assigned to one of three programming methods that will be active during sleep. Participants will answer daily questions about their gastroparesis symptoms on an application with their phone/tablet. Participants will answer quality of life questionnaires about their gastroparesis symptoms at study visits.

Participants will be involved in the study for up to six months after treatment assignment.

Programming parameters in the study are within currently approved labeling.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Percent Change in Weekly Vomiting Frequency by GCSI-DD3 Months, 6 Months

Less than a 50% increase in GCSI-DD weekly vomiting frequency from baseline

Scoring Change in Nausea Severity by GCSI-DD3 Months, 6 Months

Less than a 1-point increase in GCSI-DD nausea severity from baseline

Secondary Outcome Measures
NameTimeMethod
Mean Change from Baseline in PAGI-QoL Scores3 Months, 6 Months

Change in PAGI-QoL from baseline

Mean Change from Baseline in Quality of Sleep Scores3 Months, 6 Months

Change in Quality of Sleep from baseline

Mean Change from Baseline in GCSI-DD Weekly Vomiting Frequency3 Months, 6 Months

Change in GCSI-DD weekly vomiting frequency from baseline

Mean Change from Baseline in GCSI-DD Total Symptom Score3 Months, 6 Months

Change in GCSI-DD Total Symptom Score from baseline

Mean Change from Baseline in GCSI-DD Nausea Severity3 Months, 6 Months

Change in GCSI-DD nausea severity from baseline

Trial Locations

Locations (2)

University of Louisville

🇺🇸

Louisville, Kentucky, United States

MNGI Digestive Health, P.A.

🇺🇸

Coon Rapids, Minnesota, United States

University of Louisville
🇺🇸Louisville, Kentucky, United States
Abigail Stocker, MD
Contact

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.